Patents Assigned to ZymoGenetics
  • Adipocyte-specific protein homologs
    Patent number: 6265544
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig37, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig37 polypeptides.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: July 24, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Nuclear receptor polypeptide ZPPAR4
    Patent number: 6262234
    Abstract: The present invention relates to ZPPAR4 polynucleotide molecules and ZPPAR4 polypeptide molecules. ZPPAR4 is a novel member of the nuclear receptor superfamily. The novel ZPPAR4 nuclear receptor can be used to examine ZPPAR4-related complex transcriptional networks and biological processes. The disclosed ZPPAR4 polynucleotides and polypeptides provide a means to identify the natural ligand for ZPPAR4, as well as agonists and antagonists thereof.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: July 17, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: James L. Holloway, Laura J. Jelinek, Diane M. Durnam, Hal Blumberg
  • Method for producing proteins in transformed Pichia
    Patent number: 6258559
    Abstract: Methylotrophic yeasts are useful hosts for the production of commercially valuable recombinant proteins. However, the development of large-scale cultures of recombinant methylotrophic yeasts has been hindered by the formation of precipitation in culture media. A new soluble minimal medium overcomes this problem. Moreover, new feeding schemes provide cultures of high biomass, which produce biologically active recombinant protein.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: July 10, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Bruce L. Zamost
  • Dialkyl ureas as calcitonin mimetics
    Patent number: 6255351
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: July 3, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Compositions and methods for treating bone deficit conditions
    Patent number: 6251901
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or “linker” defined as including a covalent bond per se so 29 as to space the aromatic systems at a distance 1.5-15Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: June 26, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Gregory R. Mundy
  • Testis-specific cystatin-like protein cystatin T
    Patent number: 6245529
    Abstract: The present invention relates to cystatin T (also known as zcys3) polypeptides and polynucleotides encoding the same. Cystatin T polypeptide is testis specific and homologous to cystatin-related epididymal specific gene (CRES) and type 2 cystatins. The polypeptides would be useful for modulating spermatogenesis and may be used to study or modulate that function in in vitro or in vivo systems. The present invention also includes antibodies to the cystatin T polypeptides.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: June 12, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: James L. Holloway, Andrew L. Feldhaus
  • Testis specific glycoprotein zpep10
    Patent number: 6242588
    Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: June 5, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Christopher S. Piddington, Jeff L. Ellsworth
  • Disulfide core polypeptides
    Patent number: 6239254
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for a disulfide core protein (Zdsc1). The polypeptides, and polynucleotides encoding them, are serine proteinase inhibitors. Also disclosed are expression vectors containing polynucleotides which encode a Zdsc1 polypeptide, antibodies which specifically bind to Zdsc1 polypeptides and anti-idiotypic antibodies which neutralize the antibodies which specifically bind to Zdsc1 polypeptides.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: May 29, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Darrell C. Conklin
  • Testis-specific cystatin-like protein cystatin T
    Patent number: 6235708
    Abstract: The present invention relates to cystatin T (also known as zcys3) polypeptides and polynucleotides encoding the same. Cystatin T polypeptide is testis specific and homologous to cystatin-related epididymal specific gene (CRES) and type 2 cystatins. The polypeptides would be useful for modulating spermatogenesis and may be used to study or modulate that function in in vitro or in vivo systems. The present invention also includes antibodies to the cystatin T polypeptides.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: May 22, 2001
    Assignee: ZymoGenetics, Inc
    Inventors: James L. Holloway, Andrew L. Feldhaus
  • Kunitz domain polypeptide and materials and methods for making it
    Patent number: 6232098
    Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a sequence of amino acid residues as shown in SEQ ID NO:5, wherein the sequence is at least 90% identical to SEQ ID NO:2. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: May 15, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Donald C. Foster, Zeren Gao
  • Dialkyl ureas as calcitonin mimetics
    Patent number: 6221913
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: April 24, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Plasmid construction by homologous recombination
    Patent number: 6207442
    Abstract: Methods for preparing double stranded, circular DNA molecules comprising a region encoding a protein of interest are disclosed. One or more donor DNA fragments encoding the protein of interest are combined with an acceptor plasmid, a first DNA linker, and a second DNA linker in a Saccharomyces cerevisiae host cell whereby the donor DNA fragment is joined to the acceptor plasmid by homologous recombination of the donor DNA, acceptor plasmid, and linkers to form the closed, circular plasmid.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: March 27, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • Adipocyte-specific protein homologs
    Patent number: 6197930
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig39, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig39 polypeptides.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: March 6, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Jacqueline M. Humes
  • Chromosomal mutagenesis in Pichia methanolica
    Patent number: 6183953
    Abstract: Methods for altering a selected chromosomal locus in P. methanolica cells and cells comprising such altered loci are disclosed. A linear DNA construct comprising (i) a segment comprising a portion of the target locus in which at least one nucleotide pair is altered and (ii) a selectable marker that complements adenine auxotrophy is introduced into cells auxotrophic for adenine. The cells are cultured under selective conditions, and cells in which the linear DNA construct has been chromosomally integrated by homologous recombination are identified. The cells are then cultured under conditions whereby cells auxotrophic for adenine can be identified, and a subset of such cells in which the altered locus has been chromosomally integrated are identified.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: February 6, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • Testis-specific insulin homolog polypeptides
    Patent number: 6183991
    Abstract: The present invention provides testis-specific insulin homolog polypeptides and polynucleotides encoding the polypeptides, as well as related compositions and methods are disclosed. The polypeptides and polynucleotides may be used within methods for enhancing viability of cryopreserved sperm, for enhancing sperm motility, to enhance fertilization in methods of assisted reproduction, as contraceptives and other related uses.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: February 6, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Darrell C. Conklin, Robyn L Adams, Anna C. Jelmberg, Catherine E. Lofton-Day, Stephen R. Jaspers
  • Modified factor VII
    Patent number: 6183743
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: February 6, 2001
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
  • Stanniocalcin-2
    Patent number: 6171822
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: January 9, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Darrell C. Conklin, Si Lok, Michele Buddle, William Downey
  • Modified factor VII
    Patent number: 6168789
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: January 2, 2001
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Compositions and methods for treating bone deficit conditions
    Patent number: 6153631
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: November 28, 2000
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Gregory R. Mundy
  • Serine protease polypeptides and materials and methods for making them
    Patent number: 6153420
    Abstract: A novel serine protease is disclosed. The protease comprises a sequence of amino acid residues that is at least 95% identical to SEQ ID NO:2 from Ile, residue 111, through Asn, residue 373. Also disclosed are polynucleotide molecules encoding the protease, expression vectors containg the polynucleotides, cultured cells containing the expression vectors, and methods of making the protease. The protease can be used, inter alia, within industrial processes to degrade unwanted proteins or alter the characteristics of protein-containing compositions.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: November 28, 2000
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard